GSK AND ViiV HEALTHCARE TO SHOWCASE ADVANCES ACROSS INDUSTRY-LEADING INFECTIOUS DISEASE PORTFOLIO AT IDWEEK 2024
Media Contacts
For US-specific media inquiries, email:
melinda.x.stubbee@viivhealthcare.com
OR call +1 919 491 0831
For our corporate press office:
call +44 7557 290 420
- 60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease
- New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk
- Efficacy data for gepotidacin in patients with a high unmet need suffering from uUTIs to be shared against a backdrop of rising antimicrobial resistance
- New evidence to be shared on real-world impact of ViiV Healthcare’s innovative, long-acting HIV prevention and treatment portfolio
GSK plc (LSE/NYSE: GSK) and ViiV Healthcare will share new data from their industry-leading, prevention-focused infectious disease pipeline and portfolio at the Infectious Disease Society of America’s IDWeek 2024 annual meeting in Los Angeles from 16-19 October 2024. 60 abstracts will be presented, showcasing data for vaccines and medicines across a range of infectious diseases including respiratory syncytial virus (RSV), herpes zoster, uncomplicated urinary tract infections (uUTI) and HIV.
Vaccines
22 abstracts from GSK’s vaccines pipeline and portfolio have been accepted, including new data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) and Shingrix (Zoster Vaccine Recombinant, Adjuvanted). Presentations on GSK’s RSV vaccine will include data across different age ranges in older adults and post-marketing safety data, plus 10 other abstracts featuring evidence across comorbidities of interest, seasons and geographies. Additional presentations include overviews of GSK's 5-in-1 meningococcal ABCWY vaccine candidate and the risks of invasive meningococcal disease in young children.
Medicines
Among the abstracts from GSK’s infectious disease therapeutics portfolio, 13 abstracts will highlight data for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for uUTI and urogenital gonorrhoea (GC). This includes an oral presentation of clinical data from the EAGLE-2 and EAGLE-3 phase III trials, examining the efficacy of gepotidacin in patient subgroups with uUTIs with a high unmet need in the context of rising antimicrobial resistance (AMR). Additional data on surveillance and the burden of AMR in uUTIs and treatment failure in uUTIs will also be highlighted.
HIV prevention and treatments
Additionally, ViiV Healthcare will present 22 abstracts from its innovative HIV treatment and prevention portfolio. Two oral presentations will share real-world evidence from the OPERA and TRIO studies, evaluating the effectiveness of, adherence to and persistence in the use of Apretude (cabotegravir long-acting (LA)) for HIV pre-exposure prophylaxis (PrEP) across diverse populations.
Findings from the PILLAR study will highlight the impact of cabotegravir LA for PrEP on common challenges associated with daily oral PrEP, such as stigma and anxiety. Additional abstracts highlight ViiV’s industry-leading long-acting and two-drug regimens for the treatment of HIV including treatment benefits, satisfaction and preference, offering new insights for healthcare providers seeking to optimise care to suit individual needs and circumstances.
Tony Wood, Chief Scientific Officer, GSK said: “Infectious diseases represent a major threat to human health, which is why two-thirds of our pipeline focuses on pioneering new technologies to deliver preventative options – like vaccines and HIV PrEP – plus therapeutic solutions. At IDWeek 2024, we’re proud to share data highlighting our scientific developments in the prevention and treatment of diseases like RSV, herpes zoster, uUTI and HIV, while also working to tackle the challenge of antimicrobial resistance.”
For more than 70 years, GSK has been advancing a comprehensive portfolio of medicines and vaccines for infectious diseases. Considerable progress has been made, but there remains significant work to do to address the burden of infectious diseases on individuals, society and healthcare systems:
- More than one billion people are infected annually by seasonal respiratory viruses such as influenza and RSV.1,2 People living with certain underlying health conditions are at increased risk of hospitalisation or death due to RSV.3
- About 40 million people live with HIV worldwide, many of whom still face stigma and do not have adequate access to care.4
- AMR threatens to undermine the progress that has been made to date and prevent further gains. Without action, AMR could contribute to 40 million deaths by 2050.5
In support of its ambition to get ahead of disease, GSK continues to advance the science, pursuing new solutions while continuing to build the evidence base for its vaccines and treatments. With the breadth of data presented at IDWeek, GSK and ViiV Healthcare highlight their goal to pioneer a new range of first- or best-in-class options to close the gap in prevention and treatment for patients who deserve more.
Full list of GSK and ViiV Healthcare’s presentations at IDWeek 2024:
| Abstracts from GSK’s Vaccines Portfolio |
||
| Abstract title |
Presenting author | Presentation |
| Persistence of Immunogenicity and Safety of the Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) Administered to Adults 50–59 Years of Age (YOA) |
Corinne Vandermeulen |
Poster presentation |
| Robust and Consistent Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) Across Different Age Ranges and Frailty Status in Older Adults |
Veronica Hulstrøm | Oral presentation |
| Early Post-Marketing Safety Surveillance for the Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) | Quentin Deraedt | Oral presentation |
| Characteristics Associated with the Presence of One or More Risk Factors for Severe Respiratory Syncytial Virus Disease Among Adults in the United States | Emily K. Horn | Poster presentation |
| Risk of COPD Exacerbations, Asthma Exacerbations, and Hospitalizations for Heart Failure after RSV Hospitalization Among US Adults Aged at Least 50 Years | David Singer | Poster presentation |
| Respiratory Syncytial Virus (RSV) Testing Patterns Among Medically Attended Cases of Acute Respiratory Illness from 2016 to 2023 | David Singer | Poster presentation |
| RSV Vaccination Uptake Among US Adults Aged ≥60 Years Who Are at Increased Risk of Severe RSV Disease (August 2023–February 2024) | Elizabeth La | Poster presentation |
| Factors Associated with Healthcare Professionals’ RSV Older Adult Vaccination Knowledge and Practices During the First Season of Vaccine Availability in the United States | Elizabeth La | Poster presentation |
| Respiratory Syncytial Virus (RSV) Disease Burden in Older Adults with Acute Respiratory Infection (ARI) in Europe During the 2022/2023 RSV Season | Veronica Hulstrøm | Poster presentation |
| Coinfections with Respiratory Syncytial Virus (RSV) in a Cohort of Adults with Pre Existing Comorbidities in Wisconsin from 2015–16 through 2019–20 | Oluwakemi Alonge | Poster presentation |
| Estimating the Public Health Impact of Pertussis Decennial Booster Vaccination for German Adults | Eliana Biundo | Poster presentation |
| Quantifying the Health Equity Related Public Health Impact of Influenza Vaccination: A Pilot Study for United Kingdom | Eliana Biundo | Poster presentation |
| Medical Need for Meningococcal Vaccination in Young Children from the Americas | Oluwatosin Olaiya | Poster presentation |
| Clinical Profile of GSK's Pentavalent Meningococcal ABCWY Vaccine: An Overview | Woo-Yun Sohn | Poster presentation |
| Characterization of Herpes Zoster Cases and Sustained High Vaccine Efficacy Against Herpes Zoster Complications in Individuals Vaccinated with Recombinant Zoster Vaccine During A Long-Term Follow-Up Study | Rafael Leon | Poster presentation |
| Recombinant Zoster Vaccine Uptake Among Immunocompromised US Adults | Justin Gatwood | Poster presentation |
| Herpes Zoster Burden Among US Adults with Immunocompromising or Comorbid Conditions: A Systematic Literature Review | Justin Gatwood | Poster presentation |
| Worldwide Impact of Increased Recombinant Zoster Vaccine Coverage on the Burden of Herpes Zoster, Based on 11-Year Clinical Trial Follow-Up Data, in Adults Aged ≥50 Years | Desmond Curran | Poster presentation |
| Incidence of Diagnosed Herpes Zoster and Risk of Complications by Race and Ethnicity: A Retrospective Cohort Study Among Adults in the United States | Nikita Stempniewicz | Poster presentation |
| Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine in Inflammatory Bowel Disease Patient Populations Aged 50 Years and Older | Bradley K. Ackerson | Poster presentation |
| Recent Incidence Rate of Herpes Zoster Among Immunocompetent Adults Aged 18 and Older in the United States | Huifeng Yun | Poster presentation |
| The Adjuvanted Recombinant Zoster Vaccine Is Effective in Preventing Herpes Zoster (HZ) Among Patients ≥50 Years of Age (YOA) with Selected Autoimmune Diseases in the United States: A Real-World Database Analysis (2018–2021) |
Dagna Constenla | Poster presentation |
| Abstracts from GSK’s infectious disease medicines portfolio | ||
| Discordant Clinical and Microbiological Responses are Associated with Late Clinical Relapse in Uncomplicated Urinary Tract Infections: Pooled Analysis of EAGLE-2/EAGLE-3 Trial Data | Amanda J. Sheets | Poster presentation |
| Patient Characteristics Associated with Extended Spectrum Beta Lactamase-Producing Uropathogens: Pooled Results from Two Phase 3 Clinical Trials of Gepotidacin for the Treatment of Uncomplicated Urinary Tract Infection | Jeremy Dennison | Poster presentation |
| Efficacy of Gepotidacin Versus Nitrofurantoin in a Nitrofurantoin Not Susceptible Population: A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract Infection | Jeremy Dennison | Oral presentation |
| Impact of Empiric Treatment Failure on Clinical Outcomes and Healthcare Resource Utilization Among US Females with Uncomplicated Urinary Tract Infections | Debra L. Fromer | Poster presentation |
| Impact of High Predicted Risk of Antimicrobial Resistance on Empiric Treatment Failure in US Females with Uncomplicated Urinary Tract Infections | Debra L. Fromer | Poster presentation |
| Healthcare Resource Use and Costs of Acute Uncomplicated Cystitis in Japan | Meg Franklin | Poster presentation |
| Systematic Literature Review of Acute Cystitis or Afebrile Urinary Tract Infection in Men | Fanny S. Mitrani-Gold | Poster presentation |
| In Vitro Activity of Gepotidacin Against Klebsiella pneumoniae, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022) | Rodrigo E. Mendes | Rapid fire poster presentation |
| In Vitro Activity of Gepotidacin and Comparator Agents Against a Collection of K. pneumoniae Urine Isolates from the United States During 2019–2022 | S.J. Ryan Arends | Poster presentation |
| In Vitro Activity of Gepotidacin Against Klebsiella pneumoniae, Including Molecularly Characterized Fluoroquinolone Not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019–2022) | Rodrigo E. Mendes | Poster presentation |
| In Vitro Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Responsible for Urinary Tract Infections in the US (2019–2022) | Rodrigo E. Mendes | Poster presentation |
| In Vitro Activity of Gepotidacin Against Molecularly Characterized Neisseria gonorrhoeae Isolates Exhibiting Reduced Susceptibility to Antibacterial Agents, 2018–2021 | Mark Estabrook | Poster presentation |
| A Comparative Analysis of Resistance Rates Among Escherichia coli and Klebsiella pneumoniae Isolates Collected from the Gepotidacin Uropathogen Global Surveillance Studies and Phase 3 Uncomplicated Urinary Tract Infection Clinical Studies | Renuka Kapoor | Poster presentation |
| Activity of Ibrexafungerp and Comparator Antifungals Tested Against Candida and Aspergillus Isolates Collected from Invasive Infections in a Global Surveillance Program in 2023 | Marisa L. Winkler | Poster presentation |
| Intravenous-Line Related Complications in Patients Treated with Short Term Intravenous Antibiotics for Complicated Urinary Tract Infection and Other Infections: A Systematic Literature Review | Fanny Mitrani-Gold |
Poster presentation |
| Prevalence and Risk Factors of Antimicrobial Resistance and Multidrug Resistance in Patients with Complicated Urinary Tract Infections (cUTIs) and all UTIs: A Systematic Literature Review | Fanny Mitrani-Gold | Poster presentation |
| Abstracts from ViiV Healthcare’s portfolio | ||
| PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a diverse sample of people with HIV-1 reporting high treatment satisfaction, good adherence, and high quality of life | Andrew P. Brogan | Poster presentation |
| Real-world Experience with the Two-Drug Regimen Dolutegravir/Lamivudine for the Treatment of HIV-1 among Vulnerable People Living with HIV in Canada: Preliminary Results from a Chart Review Study | V. Paul DiMondi | Encore poster presentation |
| Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living with HIV-1 from Pregnancy Data with Combination DTG and/or 3TC Antiretroviral Therapies | William Short | Encore poster presentation |
| Real-world Virologic and Safety Outcomes in People Living with HIV-1 Using Dolutegravir (DTG) + Lamivudine (3TC) in Asia Stratified by Viral Load (VL), Including in Individuals with High VLs | Andrés Doblado-Maldonado | Encore poster presentation |
| Evaluation of Weight Gain on Incident Hypertension among People Living with HIV-1 Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Randomized Clinical Trials through 96 Weeks s | Clifford B. Jones | Encore poster presentation |
| Improved Testing for Chronic Disease Among Long-Acting Injectable Versus Daily Oral Antiretroviral Therapy Users in the OPERA Cohort | Rachel P. Weber | Poster presentation |
| Characteristics of Women Initiating CAB+RPV LA in the OPERA Cohort | Jessica Altamirano | Poster presentation |
| People with HIV in the US switching to cabotegravir + rilpivirine long-acting (CAB+RPV LA) from oral antiretroviral therapy (ART) have numerous real-world benefits, including high adherence and treatment satisfaction | Andrew Brogan | Poster presentation |
| Feasibility, Fidelity, and Effectiveness of Administering CABENUVA in Infusion Centers | Cassidy Gutner | Poster presentation |
| Use of Long-Acting Cabotegravir/Rilpivirine in People Living with HIV with Renal Transplantation | George Bchech | Poster presentation |
| PrEP Decision Factors: a CHORUS Healthcare Professional Survey | Ricky Hsu | Poster presentation |
| Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort | Ricky Hsu | Oral presentation |
| Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort | Moti Ramgopal | Oral presentation |
| Opportunities for PrEP Awareness and Engagement: A Survey among Healthcare-Seeking Cisgender Women in the US | Tonia Poteat | Poster presentation |
| Awareness and Preferences for Every 2 Month Long-acting Injectable HIV Pre-Exposure Prophylaxis (PrEP) Versus Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic | Aimee Metzner | Poster presentation |
| Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic | Deanna Kerrigan | Poster presentation |
| Patient Experiences at Month 6 after Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US | Hadrian Holder | Poster presentation |
| Improvement in Provider Experiences from Baseline to Month 12 with Integrating Cabotegravir Long-Acting (CAB LA) for PrEP into Care in an Implementation Science Trial (PILLAR) | Taimur Khan | Poster presentation |
| Change in Healthcare Professional’s Identification, Counseling, and Adherence with Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women’s Health, Primary Care, and Infectious Diseases Sites: Findings from the EBONI Study | Dylan Baker | Poster presentation |
| Week 26 Interim Analysis of Implementation and Delivery of Long-Acting Injectable Cabotegravir for PrEP in a Community Pharmacy Setting | Elyse Tung | Oral presentation |
| CD4 T-cell, CD4/CD8 Ratio Improvement and a General Reduction in Inflammatory Biomarkers with Low-Level Viremia (LLV) up to Week 192 with Fostemsavir (FTR)-Based Regimens in Individuals with Multidrug-Resistant (MDR) HIV-1 | Alftan Dyson | Encore poster presentation |
| Similar Efficacy, Safety and CD4 T-cell Increase up to Week 96 Observed with Fostemsavir (FTR)-Based Regimens in the BRIGHTE Study and Dolutegravir (DTG)-Based Regimens in the VIKING-3 Study in Individuals with Multidrug-Resistant (MDR) HIV-1 | Alftan Dyson | Encore poster presentation |
GSK in infectious diseases
GSK has pioneered innovation in infectious diseases for over 70 years, and the Company’s pipeline of medicines and vaccines is one of the largest and most diverse in the industry, with a goal of developing preventive and therapeutic treatments for multiple disease areas or diseases with high unmet needs globally. With our infectious disease innovation, we’re also helping address the growing number of infections which are resistant to existing medicines.
The development of gepotidacin has been funded in part with federal funds from the US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Agreement number HHSO100201300011C and with federal funds awarded by the Defense Threat Reduction Agency under agreement number HDTRA1-07-9-0002.
In antimicrobials, in addition to gepotidacin, GSK entered into an exclusive licence agreement with Spero Therapeutics, Inc. in September 2022 to add tebipenem HBr, a late-stage antibiotic and potential treatment for complicated urinary tract infections (cUTIs), to the pipeline and are currently enrolling for PIVOT-PO, a phase III trial. In March 2023, GSK announced an exclusive licence agreement with Scynexis for Brexafemme (ibrexafungerp tablets), a first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE), dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
| GSK enquiries | |||
| Media: | Tim Foley | +44 (0) 20 8047 5502 | (London) |
| Simon Moore | +44 (0) 20 8047 5502 | (London) | |
| Kathleen Quinn | +1 202 603 5003 | (Washington DC) | |
| Lyndsay Meyer | +1 202 302 4595 | (Washington DC) | |
| Alison Hunt | +1 540 742 3391 | (Washington DC) | |
| Investor Relations: | James Dodwell | +44 (0) 20 8047 2406 | (London) |
| Mick Readey | +44 (0) 7990 339653 | (London) | |
| Camilla Campbell | +44 (0) 7803 050238 | (London) | |
| Steph Mountifield | +44 (0) 7796 707505 | (London) | |
| Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) | |
| Frannie DeFranco | +1 215 751 4855 | (Philadelphia) | |
| ViiV enquiries | |||
| Media: | Rachel Jaikaran | +44 (0) 78 2352 3755 | (London) |
| Melinda Stubbee | +1 919 491 0831 | (North Carolina) | |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
References
- World Health Organization (WHO). Influenza (Seasonal). Available at https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed October 2024.
- National Institute of Allergy and Infectious Diseases. Respiratory Syncytial Virus (RSV). Available at: https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv. Accessed October 2024.
- Centers for Disease Control and Prevention (CDC). RSV in Older Adults. Available at: https://www.cdc.gov/rsv/older-adults/. Accessed October 2024.
- World Health Organization (WHO). The Global Health Observatory. HIV. Available at: https://www.who.int/data/gho/data/themes/hiv-aids. Accessed October 2024.
- Pulingham T., et al. Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci. 2022 Mar 1:170:106103.
